Retinitis Pigmentosa: From Basics to Advanced Clinical Knowledge

1. Definition and Overview

• Prevalence: 1 in 3,000 to 1 in 5,000 persons (approximately 1.5 million people globally)
• Age of onset: Variable - typically manifests in the first to third decade of life
• The severity at any given age varies significantly even among patients with the same gene mutation

2. Genetics and Molecular Basis

1. Phototransduction cascade - rhodopsin (RHO) mutations are the most common cause of AD-RP; over 100 RHO mutations identified
2. Retinoid cycle - RPE65, LRAT mutations
3. Photoreceptor structure - PRPH2 (peripherin), ROM1
4. Pre-mRNA splicing factors - PRPF3, PRPF8, PRPF31 (unique to retina despite ubiquitous expression)
5. Ciliary transport - RPGR, RP2 (X-linked forms); the RPGR protein localizes to the connecting cilium of rod photoreceptors

3. Pathology and Pathophysiology

1. Rod photoreceptors degenerate first → outer nuclear layer thinning
2. Progressive RPE dysfunction → lipofuscin accumulation, phagocytosis failure
3. Retinal pigment migration → pigment from RPE migrates perivascularly into the neural retina, forming "bone spicules"
4. Retinal arteriolar attenuation → secondary to reduced metabolic demand from lost photoreceptors
5. Optic nerve head atrophy → waxy pallor
6. Secondary cone degeneration → loss of central acuity occurs later

4. Clinical Features

Symptoms (in typical order of onset)

1. Nyctalopia (night blindness) - often the presenting symptom, due to rod loss
2. Ring scotoma / peripheral visual field loss - mid-peripheral visual field defect that gradually expands concentrically
3. Tunnel vision - characteristic "gun barrel" vision in advanced disease
4. Photopsia - flickering or flashing lights
5. Reduced central vision - a later feature (unless cataract intervenes earlier)

Classic Fundus Signs (the triad)

1. Bone-spicule pigmentation - bilateral, mid-peripheral, intraretinal, perivascular. Named for resemblance to cancellous bone trabeculae. Starts sparse and expands anteriorly and posteriorly over time.
2. Arteriolar attenuation - diffuse narrowing of retinal arterioles
3. Waxy disc pallor - pale/yellowish optic disc (distinct from ischemic pallor)

Associated Ocular Features

• Posterior subcapsular cataract - common in all forms
• Cystoid macular oedema (CMO) - ~15% of patients; treatable cause of visual decline
• Epiretinal membrane (ERM) - contributes to metamorphopsia
• Macular atrophy - ~40% of patients on OCT
• Open-angle glaucoma - ~3%
• Optic disc drusen - increased frequency vs. general population
• Posterior vitreous detachment

Variant Forms

5. Syndromic RP (20-30% of cases)

6. Differential Diagnosis / RP Mimics

• Drug toxicity: Chloroquine, hydroxychloroquine (bull's-eye maculopathy), thioridazine, chlorpromazine
• Infectious: Congenital rubella retinopathy, syphilitic chorioretinitis, CMV retinitis sequelae
• Traumatic: Old laser injury, retained intraocular foreign body
• Inflammatory: Diffuse unilateral subacute neuroretinitis (DUSN)
• Investigation for syphilis is sometimes warranted in atypical presentations

7. Investigations and Diagnosis

8. Prognosis

• AD-RP: Best prognosis - many retain useful vision into middle age
• AR-RP: Intermediate severity
• XLRP: Most severe - central vision often reduced to 6/60 or less by the fifth decade
• Visual field loss is progressive and irreversible; rate varies widely by genotype
• CMO and ERM are treatable causes of visual decline within RP - identifying them is clinically important

9. Current Management

Approved Treatments

• Luxturna (voretigene neparvovec, AAV2-RPE65) - the first approved retinal gene therapy; FDA approved 2017 for biallelic RPE65 mutation-associated retinal dystrophy (covers LCA2 and RPE65-RP). Delivers a functional RPE65 gene subretinally. This is currently the only approved gene therapy for an RP subtype.

Supportive/Preventive Management

• Annual follow-up to detect treatable complications (CMO, ERM, cataract)
• Cataract surgery - often significantly beneficial
• CMO treatment - carbonic anhydrase inhibitors (acetazolamide, dorzolamide); anti-VEGF in refractory cases
• Low vision aids and rehabilitation services
• Smoking cessation - smoking worsens progression
• Vitamin A palmitate 15,000 IU daily - may slow rod ERG decline modestly (Goldman-Cecil); remains controversial; contraindicated in pregnancy; requires liver function monitoring
• Vitamin E should be avoided - may accelerate cone ERG decline
• DHA (docosahexaenoic acid) supplementation has not shown additional benefit in RCTs
• Genetic counseling for family members and reproductive planning

Retinal Prosthetics (Bionic Eye)

• Argus II (Second Sight) - epiretinal prosthesis; FDA approved 2013 for advanced RP; however the company went bankrupt in 2022, leaving patients without device support - a cautionary tale in device medicine
• Alpha AMS/IMS (Retina Implant AG) - subretinal photovoltaic prosthesis; European experience

10. Recent Advances and Active Clinical Trials (2023-2026)

A. Gene-Specific AAV Gene Therapy (Subretinal Delivery)

• AAV-PDE6A (Tübingen group) - Phase 1/2 subretinal gene supplementation; published safety and vision outcomes data 2026 [PMID: 40825661]

B. Gene-Agnostic / Modifier Gene Therapy

• OCU400 (Ocugen) - AAV-NR2E3 (nuclear hormone receptor gene); acts as a "modifier" to regulate multiple retinal processes (photoreceptor development, metabolism, phototransduction, inflammation, survival). Phase 3 liMeliGhT trial fully enrolled with ~140 participants (70 RHO-RP + 70 other-gene RP); results expected early 2027. FDA clearance received 2024.
• SPVN20 (SparingVision) - gene-agnostic therapy targeting cones; NYRVANA Phase 1/2 initiated in Belgium 2025-2026, expanding to France and Ireland.

C. Optogenetic Gene Therapy

• MCO-010 / Visulyzr (Nanoscope Therapeutics) - multichannel opsin delivered to retinal cells; randomized controlled Phase 2/3 trial showed durable visual acuity gains maintained at 3 years. Rolling BLA submission to FDA initiated 2025; full submission planned H1 2026. Fast-track + orphan designation. First FDA approval of optogenetics may be imminent.
• GS030 (GenSight Biologics) - ChrimsonR opsin + wearable goggle light stimulation device (PIONEER trial); Phase 1/2b ongoing follow-up.
• ZM-02 (Zhongmou) - novel optogenetic approach; presented at ATC 2025 showing patients transitioning from complete blindness to functional vision (navigation capability, returning to cycling independently) in late-stage RP.

D. Antisense Oligonucleotides (ASO) and RNA Therapies

• Targeting dominant-negative RHO mutations with splice-switching ASOs
• QR-1123 (ProQR) - intravitreal ASO for P23H RHO-RP (most common AD-RP mutation in N. America); Phase 2/3 ILLUMINATE trial ongoing
• RNA base editing approaches being developed for dominant RHO variants

E. CRISPR / Gene Editing

• CRISPR-Cas9 editing for P23H rhodopsin (dominant negative) - approaches include "knock-and-replace" (silence mutant allele + deliver corrected copy)
• Subretinal CRISPR delivery proof-of-concept established in animal models
• No completed clinical trials yet in RP specifically, though LCA10 (CEP290) CRISPR editing (EDIT-101) established clinical feasibility in related disease

F. Cell-Based Therapies

• Stem cell / retinal progenitor cells (jCell, jCyte Inc.) - intravitreal injection of human retinal progenitor cells; Phase 2 results showed visual improvement in some patients; neuroprotective rather than replacement mechanism proposed
• iPSC-derived photoreceptor replacement (OpCT-001, BlueRock Therapeutics) - CLARICO trial: first-in-human iPSC-derived photoreceptor cell therapy; Phase 1 safety initiated July 2025 (up to 54 adults; dose-escalation design). A landmark in regenerative ophthalmology.

G. Neuroprotection

• CNTF (ciliary neurotrophic factor) - encapsulated cell technology (ECT) implants releasing CNTF; Phase 2 trials showed limited functional benefit despite some structural preservation
• Rod-derived cone viability factor (RdCVF) - TLQP-21 analog; neuroprotective for cones; being evaluated
• A 2026 systematic review (PMID: 42297463) examined neuroprotective therapies for visual acuity preservation - evidence remains limited for most agents

11. Key Trials Summary Table

12. The Horizon: What's Coming

• Gene-agnostic therapies (optogenetics, modifier genes) are likely to reach patients before gene-specific approaches for most RP subtypes, simply because of scale and reduced need for genotyping
• MCO-010 (Nanoscope) is the closest to FDA approval for any RP treatment since Luxturna (2017) - and it targets all forms of late-stage RP
• iPSC-derived photoreceptor transplantation represents the theoretical endpoint - structural restoration of lost cells - but faces enormous challenges in synaptic integration
• Natural history studies and biomarker development (ellipsoid zone area on OCT, FAF ring diameter, mfERG) are refining clinical trial endpoints and patient selection
• Artificial intelligence is being applied to predict progression from retinal imaging and genotype-phenotype correlations

13. Quick Reference - High-Yield Points

• RP = rod-cone dystrophy, NOT inflammatory
• Classic triad: bone spicules + arteriolar attenuation + waxy disc pallor
• Night blindness → ring scotoma → tunnel vision → central loss

• 100 causative genes; RHO (AD), RPGR (XL), USH2A (AR) are most common

• Only approved RP-type gene therapy: Luxturna (RPE65 mutations)
• Treatable complications: CMO (CAI), cataract, ERM
• Vitamin A 15,000 IU/day may slow progression; avoid Vitamin E
• XLRP gene therapy trials active with bota-vec failure and laru-zova advancing
• Optogenetic therapy (MCO-010) in rolling FDA BLA - mutation-agnostic
• First iPSC photoreceptor cell trial (CLARICO) began July 2025

• Harrison's Principles of Internal Medicine 22E (2025), p. 275
• Kanski's Clinical Ophthalmology 10th Ed., p. 646-649
• Robbins, Cotran & Kumar Pathologic Basis of Disease, p. 1912-1916
• Goldman-Cecil Medicine International Ed.
• Lam BL et al. XIRIUS trial. Ophthalmology 2024 [PMID: 38423215]
• Michaelides M et al. AAV5-RPGR Phase 1/2. Am J Ophthalmol 2024 [PMID: 38871269]
• Sherratt-Mayhew S et al. Neuroprotective therapies systematic review. BMJ Open Ophthalmol 2026 [PMID: 42297463]
• Yang P et al. AGTC-501 HORIZON 24-mo. Am J Ophthalmol 2025 [PMID: 39643074]
• Reichel FF et al. PDE6A subretinal gene therapy. Br J Ophthalmol 2026 [PMID: 40825661]
• Foundation Fighting Blindness / Drug Discovery News / Eye Health Institute 2025-2026

• MCO-010 (Visulyzr) by Nanoscope is furthest along overall - rolling BLA filed with FDA, full submission expected H1 2026. It's mutation-agnostic, meaning it could treat any RP patient with surviving inner retinal cells.

• Laru-zova (Beacon) is the strongest XLRP-specific candidate after bota-vec (MeiraGTx/J&J) failed its Phase 3 LUMEOS trial in May 2025 - a major setback for the field.
• OCU400 (Ocugen) is the only gene-agnostic modifier gene therapy in Phase 3, with 140 patients enrolled across RHO and non-RHO RP.

• CLARICO (BlueRock) - the world's first iPSC-derived photoreceptor cell transplant trial, with the first patient treated in July 2025.

Section 1 - Gene-Specific AAV Therapy (Mutation-Dependent)

Laru-zova (Laruparetigene zovaparvovec) - Beacon Therapeutics

• SKYLINE (Ph2): 36-month data presented EURETINA 2025 - durable microperimetry improvements in the high-dose arm, sustained through 3 years
• DAWN (Ph2): 15 men who had their first eye treated in SKYLINE received their second eye. Average gain: +16 ETDRS letters (3 lines) of low-luminance visual acuity (LLVA), plus microperimetry improvements
• VISTA (Ph2/3 PIVOTAL): Enrollment complete as of 2025; topline results expected H2 2026. Primary endpoint is LLVA, which is more sensitive than standard BCVA in dim conditions - the real-world relevant measure for XLRP patients
• LANDSCAPE trial: Newly launched study evaluating bilateral dosing safety (both eyes treated from the start)

Botaretigene sparoparvovec (bota-vec) - MeiraGTx

Cotoretigene toliparvovec (BIIB112) - Biogen

AAV-PDE6A - University of Tübingen

Section 2 - Gene-Agnostic / Modifier Therapy

OCU400 (NR2E3) - Ocugen

SPVN20 - SparingVision

Section 3 - Optogenetic Gene Therapy

MCO-010 / Visulyzr - Nanoscope Therapeutics

• Phase 1/2a (5-year follow-up, completed 2025): Safe and well tolerated throughout. No serious ocular adverse events.
• RESTORE Phase 2/3 RCT: Randomized, controlled, multicenter. Primary endpoint at Year 1: 40% of treated patients improved ≥10 ETDRS letters vs 0% sham (severely visually impaired patients - hand motions, light perception only at baseline).
• REMAIN extension (152 weeks = ~3 years): Average BCVA gain from baseline of +0.3 LogMAR (~15 letters, 3 lines) maintained at Week 152. BCVA area-under-the-curve was 5× greater than sham. Only 1 mild inflammation case requiring topical steroids; 14 of 15 treated patients needed no ongoing inflammation management.
• Presented at AAO 2025, Retina Society 2025, EURETINA 2025, Macula Society 2026 (Wills Eye Hospital's Dr. Allen Ho is a key investigator)
• FDA designations: Fast Track, Orphan Drug (RP + Stargardt disease)
• Rolling BLA initiated June 2025 - the first sections submitted; full package expected H1 2026
• Pipeline expansion: STARLIGHT Phase 2 in Stargardt disease complete; Phase 3 planned; preclinical programs in LCA and geographic atrophy

GS030 - GenSight Biologics

Section 4 - Antisense Oligonucleotide / RNA Therapy

QR-1123 - ProQR Therapeutics

Ultevursen - Sepul Bio

Section 5 - Cell-Based Therapy

OpCT-001 - BlueRock Therapeutics (Bayer)

jCell (Famzeretcel) - jCyte

DSP-3077 (Retinal Sheets) - Sumitomo Pharma

Section 6 - Neuroprotection & Small Molecules

N-Acetylcysteine (NAC) - Nacuity

RHO Small Molecule - Octant Bio

Bottom Line: Where the Field Stands in 2026